We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Noninvasive Cholesterol Testing Becomes Available to Public

By LabMedica International staff writers
Posted on 14 Jun 2011
Print article
Noninvasive cholesterol testing technology will be available to the public through a clinical reference laboratory testing for the first time.

PreVu is a noninvasive risk assessment technology that evaluates the additional risk a person may have for coronary artery disease (CAD) by conveniently and painlessly testing their skin cholesterol level.

High levels of skin cholesterol have been shown to be correlated to CAD as measured by stress test, angiography, coronary calcium, carotid intima-media thickness, inflammatory markers of vascular disease, previous heart attack incidents, and Framingham risk score.

Miraculins Inc. (Winnipeg, Canada), a medical diagnostic company focused on developing and commercializing diagnostic tests and risk assessment tools for unmet clinical needs, has signed a Letter of Intent with Gamma-Dynacare Medical Laboratories (Brampton, Canada), one of Canada's largest and medical laboratories, to introduce a laboratory processed format of its PreVu noninvasive cholesterol test technology.

Under the terms of the agreement, Gamma-Dynacare will be responsible for all costs related to the final development stages of the PreVu LP test as well as the development and implementation of an automated system to process the test at a centralized facility. Gamma-Dynacare will also provide logistical support for collection, transportation and results reporting utilizing Gamma's internal infrastructure, which handles tens of thousands of specimens daily, and delivers more than 40 million tests annually. As part of the agreement, Miraculins has awarded Gamma-Dynacare the exclusive rights to process all PreVu LP Tests sold in Canada.

The PreVu LP test noninvasively measures the amount of cholesterol that has been deposited in skin tissues by painlessly and rapidly collecting skin cells from the palm of the hand using a medical adhesive collection device, which would then be sealed and sent to a Gamma-Dynacare laboratory for processing. The sample collection process is easily self-performed, takes 15 sec. to conduct, and does not require fasting.

Related Links:

Miraculins Inc.
Gamma-Dynacare Medical Laboratories


New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Automated Blood Typing System
IH-500 NEXT
New
17 Beta-Estradiol Assay
17 Beta-Estradiol Assay
New
Free Human Prostate-Specific Antigen CLIA
LIAISON fPSA

Print article

Channels

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.